Tăng tiểu cầu tiên phát và bệnh mạch vành

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Văn Đạt Lê, Xuân Thận Lê, Ngọc Quang Nguyễn, Thị Thu Hường Nguyễn, Xuân Tùng Ngô Thị Kim Oanh Nguyễn, Đắc Bắc Phùng

Ngôn ngữ: Vie

Ký hiệu phân loại: 612.1 Blood and circulation

Thông tin xuất bản: Tim mạch học Việt Nam 2023

Mô tả vật lý: 76-81

Bộ sưu tập: Metadata

ID: 408932

Thêm vào giỏ Liên kết toàn văn

Tóm tắt
Chủ đề

Tăng tiểu câu tiên phát (Essential Throbocythemia - ET) là bệnh lý liên quan đến tăng sinh tủy đơn dòng, làm gia tăng nguy cơ huyết khối và chảy m áu1J. Các nghiên cứu gân đây cho thấy các biến cố do huyết khối, đặc biệt là huyết khối ở mạch não, mạch vành, và mạch ngoại biên thường gặp hơn so với biến cố chảy m áu3-4. Các yếu tố làm tăng nguy cơ huyết khối của bệnh nhân bao gôm: có tiễn sử huyết khối, tuổi >
60, có đột biến JAK21/617F5. Mặc dù liên quan đến các biến cố huyết khối nhưng nhôi máu cơ tim lại ít được báo cáo trên các bệnh nhân có tăng tiều cầu tiên p h á t&7. Trong một nghiên cứu, tỉ suất gặp hội chứng vành cấp ở nhóm bệnh nhãn này được báo cáo khoảng 9,4% và thường gặp ở người trên 40 tuổi8. Bên cạnh đó, tăng tiểu câu tiên phát liên quan đến suy giảm lưu lượng vành dự trữ (Coronary Flow Reserve - CFR)9 và gia tăng gánh nặng vôi hóa trên hệ động mạch vành'0-" , đặc biệt ở nhóm bệnh nhân có đột biệtJAK2 V617F. Chúng tôi xin báo cáo 2 trường hợp lâm sàng có bệnh lý động mạch vành và tăng tiều câu tiên phát được điều trị tại bệnh viện, Tóm tắt tiếng anh, Essential Throbocythemia (ET) is a monoclonal myeloproliferative disease that increases the risk ofthrombosis and bleeding12. Recent research has shown that thromboembolic events especially cerebral, coronary and peripheral vascular thrombosis are more common than bleeding events3-4. Factors that increase the patient's risk o f thrombosis include: a history of thrombosis, above the age o f 60 andJAK21/617F5 mutation. Inspiteofitsassociation with thromboembolicevents, myocardial infarctions are rarely reported on patients with ET6-7. In one study, the rate o f occurrence of acute coronary syndrome in this patient group is reported to be about 9.4% and is commonly found in people over 40 years of age8. In addition, ET is associated with Coronary Flow Reserve (CFR) and increased calcification load on coronary arteries, especially in the patient group withJAK2 V617F mutation. We would like to report 2 clinical cases with coronary artery disease and primary thrombocythemia treated at our hospital.

Tạo bộ sưu tập với mã QR